ReviewOncogenesis2020
Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges.
Review in Oncogenesis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis.Journal of cancer research and clinical oncology · 2023Pooled it
- The prognostic value of tumor macroscopic morphology in colorectal cancer.Translational oncology · 2026Article
- AI-enabled multi-omics integration in colorectal cancer: from molecular stratification to clinical translation.Frontiers in cell and developmental biology · 2026Review
- In Silico Analysis of the Dual Role of Tumor Microenvironment on Colon Cancer Subtypes.Cancer informatics · 2026Article
- Identification of programmed cell death-related subtypes reveals immune heterogeneity and therapeutic divergence in colon cancer.Theranostics · 2026Article
- Integrative multi-omics analysis identifies a CMA-associated heterogeneity risk score and a cDCs-based immune score for robust prognostic stratification in colon cancer with single-center and experimental validation.Frontiers in immunology · 2026Article
- Preoperative HALP and LMR predict disease-free survival in stage III colon cancer and enable nomogram-based risk stratification.Frontiers in oncology · 2026Article
- Consensus Molecular Subtypes (CMS) Classification: a progress towards Subtype-Driven treatments in colorectal cancer.World journal of surgical oncology · 2025Review
- Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI.Communications medicine · 2025Article
- Prognostic and therapeutic potential of disulfidptosis-related genes in colon adenocarcinoma: a comprehensive multi-omics study.Cancer cell international · 2025Article
- Integrative multi-omics analysis reveals the LncRNA 60967.1-PLCD4-ATRA axis as a key regulator of colorectal cancer progression and immune response.Molecular cancer · 2025Article
- Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer.iScience · 2025Article
- Mushroom-derived bioactive compounds pharmacological properties and cancer targeting: a holistic assessment.Discover oncology · 2025Review
- NanoCMSer: a consensus molecular subtype stratification tool for fresh-frozen and paraffin-embedded colorectal cancer samples.Molecular oncology · 2025Article
- Heterogeneity in Cancer.Cancers · 2025Review
- Not seeing the trees for the forest. The impact of neighbours on graph-based configurations in histopathology.BMC bioinformatics · 2025Article
- Unveiling Theranostics: Nanocomplex-Assisted Photodynamic Eradication of Aggressive Cancer Cells and Modulation of Tumor-Associated Macrophages.International journal of nanomedicine · 2025Article
- Article
- First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?Current oncology reports · 2024Review
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colon cancer inter-tumour heterogeneity is installed on multiple levels, ranging from (epi)genetic driver events to signalling pathway rewiring reflected by differential gene expression patterns. Although the existence of heterogeneity in colon cancer has been recognised for a longer period of time, it is sparingly incorporated as a determining factor in current clinical practice. Here we describe how unsupervised gene expression-based classification efforts, amongst which the consensus molecular subtypes (CMS), can stratify patients in biological subgroups associated with distinct disease outcome and responses to therapy. We will discuss what is needed to extend these subtyping efforts to the clinic and we will argue that preclinical models recapitulate CMS subtypes and can be of vital use to increase our understanding of treatment response and resistance and to discover novel targets for therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.